Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 9th Euro-Global Gastroenterology Conference Valencia, Spain.

Day 1 :

Keynote Forum

Maxwell Mani Chait

Columbia University College of Physicians, USA

Keynote: Gastroesophageal Reflux Disease in the Older Patient

Time : 10.00- 10.45 AM

OMICS International Gastro Congress 2016 International Conference Keynote Speaker Maxwell Mani Chait photo

Maxwell M Chait completed his MD degree at the age of 25 from the University of California School of Medicine at San Francisco. He is a Fellow of several prestigious organizations, including the American College of Physicians, American College of Gastroenterology, American Gastroenterological Association and the American Society for Gastrointestinal Endoscopy. He is a practicing gastroenterologist on the faculty of the Columbia University College of Physicians and Surgeons. He has authored more than 40 publications in reputed journals. He is the editor-in-chief of the Journal of Liver Disease and Transplantation and serves on the editorial board of the World Journal of Gastrointestinal Endoscopy.


Gastroesophageal reflux disease is the most common upper gastroenterology disorder in the US. It is associated with a variety of complications and significantly impacts quality of life. Proton pump inhibitors are the most effective treatment. Dexlansoprazole modified release (MR) is a proton pump inhibitor that employs a novel release formulation that prolongs its absorption and allows for more flexibility in dosing. Dexlansoprazole MR can be dosed without regard to food intake or time of day, and once-daily dosing may replace twice-daily dosing of other agents. Dexlansoprazole MR is effective for healing and maintenance of erosive esophagitis, and for the treatment of nonerosive disease, including nocturnal gastroesophageal reflux disease. Dexlansoprazole MR is safe and well tolerated, and can improve quality of life.

Keynote Forum

Steven Teich

Nationwide Children’s Hospital, USA

Keynote: Shocking the GI tract: Electrical stimulation from top to bottom

Time : 10.45- 11.30 AM

OMICS International Gastro Congress 2016 International Conference Keynote Speaker Steven Teich photo

Steven Teich, MD graduated from The State University of New York at Buffalo College of Medicine. He completed a General Surgery Residency at George Washington University Hospital and a Pediatric Surgery Fellowship at the University of Pittsburgh. He is board certified in General Surgery, Pediatric Surgery, and Surgical Critical Care. He was Director of the Surgical Neuromodulation Program at Nationwide Children’s Hospital, Columbus, OH. He has published 57 peer-reviewed papers and 16 book chapters and edited a book entitled Reoperative Pediatric Surgery. He serves on the editorial board of two journals and is an ad hoc reviewer for many journals.


Electrical stimulation of the gastrointestinal tract has been touted as a possible therapy for intestinal motor dysfunction since 1963 when Bilgutay, et al., reported the use of transluminal electrical stimulation to induce peristalsis. In the late 1960’s and 1970’s the myoelectrical activity of the gastrointestinal tract was elucidated along with its relationship to gut contractility. Out of this initial research several clinical applications of gastrointestinal electrical stimulation have arisen. These include gastric electrical stimulation (GES) for treatment of gastroparesis, sacral nerve stimulation (SNS) for treatment of fecal incontinence and constipation, and electrical stimulation of the lower esophageal sphincter (LES) for treatment of severe gastroesophageal reflux disease (GERD). GES is a low energy, high frequency system that stimulates the nerves that innervate the gastric antral muscle. GES improves nausea and vomiting, decreases medical costs, decreases hospital days, and improves quality of life in patients with gastroparesis refractory to dietary and pharmacological interventions. SNS is a low energy, high frequency system that directly stimulates the third sacral nerve root. SNS significantly improves severe fecal incontinence and constipation compared with optimal medical therapy. Electrical stimulation of the LES for treatment of GERD is the newest electrical stimulation therapy. Studies published in the last 2 years demonstrate sustained improvement in GERD outcome and GERD-HRQL, elimination of the need for daily GERD medications, and sustained normalization of esophageal acid exposure compared to standard medical therapy for severe GERD. Electrical stimulation of the gastrointestinal tract continues to have great potential for many GI disorders.

Keynote Forum

Khalil N Bitar

Wake Forest Institute, USA

Keynote: What the future holds for tissue engineering in the GI tract

Time : 11.45- 12.30

OMICS International Gastro Congress 2016 International Conference Keynote Speaker Khalil N Bitar photo

Khalil N Bitar PhD AGAF is Professor of Regenerative Medicine, Gastroenterology, Physiology and Biomedical Engineering. He is the director of Gastroenterology program at the Wake Forest Institute for Regenerative Medicine. He has published more than 100 papers in high impact journals and has been funded by NIH for more than 30 years. He is a fellow of the American Gastroenterolgy Association.


Tissue engineering and regenerative medicine aim to restore, repair, or regenerate the function of the tissues. Gastrointestinal tissue engineering is a challenging process given the specific phenotype and alignment of each cell type that colonizes the tract. These properties are critical for proper functionality. Regeneration of the neuromuscular apparatus is of critical importance. New materials are emerging. Regeneration can be divided into acellular approaches such as decellularized matrices, synthetic and natural scaffolds as replacements to reconstruct the gut, or cell-based approaches such as tissue specific cells (smooth muscle cells, neural progenitor cells, and epithelial cells), gut derived organoid units, and stem cells (organ buds). New stem cell strategies for in vitro modelling and in vivo therapies are emerging.